Literature DB >> 16523821

Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.

G B Fogarty, M Bayne, P Bedford, R Bond, G Kannourakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16523821     DOI： 10.1016/j.clon.2005.11.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  4 in total

1.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Authors:  Carla Casulo; Jocelyn Maragulia; Andrew D Zelenetz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

2.  Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Authors:  Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 3.  Rituximab maintenance in indolent lymphoma: indications and controversies.

Authors:  Marinus H J van Oers
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 4.  Human cutaneous B cells: what do we really know?

Authors:  Irina Lerman; Drew C Mitchell; Christopher T Richardson
Journal:  Ann Transl Med       Date:  2021-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.